secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0000950170-24-043519
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics receives Nasdaq delisting notice for stockholders' equity deficit
--------------------------------------------------------------------------------

- Stockholders' deficit of $229,000 at Dec 31, 2023 violates Nasdaq's $2.5M minimum equity requirement.
- Company received delisting notice on April 5, 2024; must submit compliance plan by May 20, 2024.
- If Nasdaq accepts plan, extension possible through Oct 2, 2024 to regain compliance.
- Failure to regain compliance may result in delisting; company can request hearing to stay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024043519/0000950170-24-043519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024043519/aktx-20240405.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-043519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer